Exicure, Inc. XCUR

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
34/100
Developing

About Exicure, Inc.

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California. Full XCUR analysis →

Competitive advantage assessment

Key risks

  • ROIC Below WACC or Peers ROIC at 32.3th percentile suggests inefficient capital deployment.
  • Below-Peer Operating Efficiency Operating margin at 30.6th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
30

Where XCUR ranks in Biotechnology

Exicure, Inc. ranks #458 of 713 scored companies in Biotechnology by moat score — the top 64%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near XCUR in Biotechnology
# Company Moat score Rating
454 Cardiff Oncology, Inc. CRDF 34/100 Developing
455 KALA BIO, Inc. KALA 34/100 Developing
456 Biodexa Pharmaceuticals plc BDRX 34/100 Developing
457 RAPT Therapeutics, Inc. RAPT 34/100 Developing
458 Exicure, Inc. XCUR 34/100 Developing
459 MetaVia Inc. MTVA 34/100 Developing
460 Polyrizon Ltd. PLRZ 34/100 Developing
461 Lixte Biotechnology Holdings, I LIXT 34/100 Developing
462 Atossa Therapeutics, Inc. ATOS 34/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How XCUR scores on the Corporate Default defenses

Pricing Power

Score 30 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 27 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 30 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 25 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 39 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 53 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding XCUR's moat

What is Exicure, Inc.'s moat score?

Exicure, Inc. (XCUR) scores 34 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #458 of 713 scored companies in Biotechnology, the top 64%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (53/100) and its weakest is Capital Efficiency (25/100).

How does Exicure, Inc. compare with other Biotechnology companies?

Exicure, Inc. ranks #458 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are RAPT Therapeutics, Inc. (RAPT) at 34 just above it and MetaVia Inc. (MTVA) at 34 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Exicure, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Exicure, Inc.?

The Corporate Default template measures 6 defenses, and XCUR scores: Pricing Power (30), Cost Advantage (27), Customer Stickiness (30), Capital Efficiency (25), Resilience (39), Scale & Market Position (53). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000